Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Zinc finger protein 367 promotes metastasis by inhibiting the Hippo pathway in breast cancer

Oncogene volume 39, pages 2568–2582 (2020)Cite this article

Subjects

Abstract

Circulating tumor cells (CTC) disseminating is an important cause of distant metastasis. However, the mechanism involved in increasing the numbers of CTCs in breast cancer is unclear. Herein, Zinc finger protein 367 (ZNF367) was identified as a potential prometastatic gene in an integrative breast cancer datasets. ZNF367 was upregulated in breast cancer tissues and cell lines, and significantly correlated with poorer metastasis-free and overall survivals in patients. ZNF367 promoted tumor metastasis accompanied with increase of CTC numbers. Mechanistically, ZNF367 interacted with chromatin remodeling protein BRG1 and transcriptionally activated CIT and TP53BP2, leading to the inhibition of the Hippo pathway and activation of YAP1, which gave rise to the resistance of anoikis and increased CTCs in the blood circulation. More importantly, administration of a YAP1 inhibitor Verteporfin resensitized ZNF367-overexpressing breast cancer cells to anoikis and abrogated metastasis. Our findings addressed the importance of ZNF367 in breast cancer as a prognostic biomarker and offered a potential therapeutic strategy for the treatment of a subset of metastatic breast cancer with ZNF367 overexpression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: High expression of ZNF367 correlates with breast cancer metastasis and poor prognosis.
Fig. 2: ZNF367 promotes breast cancer metastasis by increasing the presence of CTCs.
Fig. 3: ZNF367 inhibits anoikis in breast cancer.
Fig. 4: ZNF367 activates YAP1 signaling.
Fig. 5: ZNF367 directly activates two negative regulators of the Hippo signaling pathway.
Fig. 6: Pharmacological targeting of YAP1 inhibits ZNF367-driven breast cancer metastasis.
Fig. 7: Clinical relevance of ZNF367 with YAP1 and CTCs in breast cancer patients.

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68:394–424.

  2. Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, et al. Distant metastasis in triple-negative breast cancer. Neoplasma. 2013;60:290–4.

    Article  CAS  Google Scholar 

  3. Lin E, Cao T, Nagrath S, King MR. Circulating tumor cells: diagnostic and therapeutic applications. Annu Rev Biomed Eng. 2018;20:329–52.

    Article  CAS  Google Scholar 

  4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl J Med. 2004;351:781–91.

    Article  CAS  Google Scholar 

  5. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23:1420–30.

    Article  Google Scholar 

  6. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl J Med. 2008;359:366–77.

    Article  CAS  Google Scholar 

  7. Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106:dju066. pii

    Article  Google Scholar 

  8. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13:688–95.

    Article  Google Scholar 

  9. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014;16:440.

    Article  Google Scholar 

  10. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res. 2001;61:333–8.

    CAS  PubMed  Google Scholar 

  11. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–91.

    Article  CAS  Google Scholar 

  12. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430:1034–9.

    Article  CAS  Google Scholar 

  13. McFall A, Ulku A, Lambert QT, Kusa A, Rogers-Graham K, Der CJ. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol Cell Biol. 2001;21:5488–99.

    Article  CAS  Google Scholar 

  14. Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di GH, et al. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res. 2013;19:1389–99.

    Article  CAS  Google Scholar 

  15. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 2008;15:1752–9.

    Article  CAS  Google Scholar 

  16. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246–57.

    Article  CAS  Google Scholar 

  17. Zhang X, Zhang L, Lin B, Chai X, Li R, Liao Y, et al. Phospholipid phosphatase 4 promotes proliferation and tumorigenesis, and activates Ca(2+)-permeable Cationic Channel in lung carcinoma cells. Mol Cancer. 2017;16:147.

    Article  Google Scholar 

  18. Asano H, Murate T, Naoe T, Saito H, Stamatoyannopoulos G. Molecular cloning and characterization of ZFF29: a protein containing a unique Cys2His2 zinc-finger motif. Biochem J. 2004;384:647–53.

    Article  CAS  Google Scholar 

  19. Zhang X, Zhou H, Zhang Y, Cai L, Jiang G, Li A, et al. ZNF452 facilitates tumor proliferation and invasion via activating AKT-GSK3beta signaling pathway and predicts poor prognosis of non-small cell lung cancer patients. Oncotarget. 2017;8:38863–75.

    PubMed  PubMed Central  Google Scholar 

  20. Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, et al. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015;6:7351.

    Article  CAS  Google Scholar 

  21. Gao Y, Zhu Y, Zhang Z, Zhang C, Huang X, Yuan Z. Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization. J Exp Clin Cancer Res. 2016;35:66.

    Article  Google Scholar 

  22. Ren C, Han C, Fu D, Wang D, Chen H, Chen Y, et al. Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy. Int J Cancer. 2016;138:1586–1600.

    Article  CAS  Google Scholar 

  23. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA. 2012;109:E2441–50.

    Article  CAS  Google Scholar 

  24. Lu C, Allis CD. SWI/SNF complex in cancer. Nat Genet. 2017;49:178–9.

    Article  CAS  Google Scholar 

  25. Gibault F, Bailly F, Corvaisier M, Coevoet M, Huet G, Melnyk P, et al. Molecular features of the YAP inhibitor verteporfin: synthesis of hexasubstituted dipyrrins as potential inhibitors of YAP/TAZ, the downstream effectors of the Hippo pathway. ChemMedChem. 2017;12:954–61.

    Article  CAS  Google Scholar 

  26. Jain M, Zhang L, Boufraqech M, Liu-Chittenden Y, Bussey K, Demeure MJ, et al. ZNF367 inhibits cancer progression and is targeted by miR-195. PLoS ONE. 2014;9:e101423.

    Article  Google Scholar 

  27. Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14:611–22.

    Article  CAS  Google Scholar 

  28. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431:1112–7.

    Article  CAS  Google Scholar 

  29. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 2006;10:203–14.

    Article  CAS  Google Scholar 

  30. McCarthy N. Metastasis: understanding the prowess of mutant p53. Nat Rev Cancer. 2014;14:385.

    Article  CAS  Google Scholar 

  31. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014;26:136–49.

    Article  CAS  Google Scholar 

  32. de Groot AF, Kuijpers CJ, Kroep JR. CDK4/6 inhibition in early and metastatic breast cancer: a review. Cancer Treat Rev. 2017;60:130–8.

    Article  Google Scholar 

  33. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat cell Biol. 2013;15:637–46.

    Article  CAS  Google Scholar 

  34. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012;18:1511–7.

    Article  CAS  Google Scholar 

  35. Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30:1–17.

    Article  CAS  Google Scholar 

  36. Wang W, Li X, Huang J, Feng L, Dolinta KG, Chen J. Defining the protein-protein interaction network of the human hippo pathway. Mol Cell Proteom. 2014;13:119–31.

    Article  CAS  Google Scholar 

  37. Espanel X, Sudol M. Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem. 2001;276:14514–23.

    Article  CAS  Google Scholar 

  38. Sinn HP, Helmchen B, Wittekind CH. TNM classification of breast cancer: changes and comments on the 7th edition. Pathologe. 2010;31:361–6.

    Article  Google Scholar 

  39. Zhang Z, Li J, Zheng H, Yu C, Chen J, Liu Z, et al. Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma. Cancer Epidemiol Biomark Prev. 2009;18:2685–93.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by National Natural Science Foundation of China (No. 81772800); Fundamental Research Funds for the Central Universities (No. 2017KFYXJJ258).

Author information

Author notes

  1. These authors contributed equally: Xianqiu Wu, Xin Zhang, Liang Yu

Authors and Affiliations

  1. State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China

    Xianqiu Wu, Xin Zhang, Liping Ye, Yue Li, Xiaoqing Sun, Ying Ouyang, Xiangfu Chen, Libing Song & Xi Lin

  2. The department of gastrointestinal surgery, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, 529030, China

    Xianqiu Wu

  3. Clinical Experimental Center, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, 529030, China

    Xin Zhang & Dong Ren

  4. Department of Vascular and Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China

    Liang Yu

  5. Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Chen Zhang

  6. Institute of Structural & Molecular Biology, Division of Biosciences, University College London, London, WC1E 6BT, UK

    Lefan Yu

  7. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Pian Liu

  8. Ultrasonic Department, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China

    Xi Lin

Authors
  1. Xianqiu Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liping Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dong Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yue Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaoqing Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lefan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ying Ouyang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xiangfu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Libing Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Pian Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Xi Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

PL and XL designed the project. XW, XZ, and LY carried out most of the experimental work. XW and XZ conducted the bioinformatic analysis, immunohistochemistry staining, and in vivo studies. CZ, LY, YL, and XS conducted western blot analysis, plasmid constructs, and immunoprecipitation. LY, YO, and XC conducted cell culture and PCR analysis. DR conducted language editing. PL and XL wrote the manuscript. LS, PL, and XL supervised the project.

Corresponding authors

Correspondence to Pian Liu or Xi Lin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, X., Zhang, X., Yu, L. et al. Zinc finger protein 367 promotes metastasis by inhibiting the Hippo pathway in breast cancer. Oncogene 39, 2568–2582 (2020). https://doi.org/10.1038/s41388-020-1166-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-020-1166-y

This article is cited by

Search

Advanced search

Quick links